Revised SPC: Cardioxane (dexrazoxane) 500 mg powder for solution for infusion

Source:
electronic Medicines Compendium - eMC
Publisher:
electronic Medicines compendium
Publication date:
20 September 2017

Abstract

A number of changes have been made to the SPC, including addition/updating of information relating to use in the paediatric population, and contraindication in children planned to receive a cumulative dose of <300 mg/m2 of doxorubicin (or equivalent dose of another anthracycline)